Events & Presentations Upcoming Events 43rd Annual J.P. Morgan Healthcare Conference Jan 15, 2025 at 7:30 AM PST Click here for webcast Add to Outlook Add to Google Calendar Past Events Stifel Healthcare Conference Nov 18, 2024 at 2:25 PM EST Click here for webcast Investor Presentations ARS Pharma Corporate Presentation ARS Pharma Corporate Presentation 6.1 MB Aug 9, 2024 neffy® FDA Approval Call On August 9, 2024, we announced the FDA approval of neffy for adults and children 30 kg or greater in body weight. Supporting Materials neffy FDA Approval Call (August 2024) 5.9 MB Mar 7, 2024 at 1:00 PM EST Neffy® Investor Day On March 7, 2024, we hosted a virtual neffy Investor Day event showcasing the neffy product profile and anticipated commercialization strategy, including presentations from ARS Pharma senior management, as well as guest speakers. To view the webcast, click here Supporting Materials neffy investor day presentation (Mar 2024) 10.1 MB Scientific Publications JACI: In Practice Self-Administration Dosing Publication Adult pharmacokinetics of self-administration of epinephrine nasal spray 2.0 mg… JACI 2023 Single and Repeat Dose Publication Pharmacokinetics/pharmacodynamics of epinephrine after single and repeat admini… Scientific Presentations AAAAI 2024 Epinephrine Utilization A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB AAAAI 2024 Poster CMC Comparative Stability of Three Epinephrine Products Under Extreme Temperature Conditions 514.3 KB AAAAI 2024 Poster EPI 10 Pediatric Doses of neffy (epinephrine nasal spray) Demonstrate Pharmacokinetic Profiles Equivalent to Epinephrine Injection Products 649 KB ACAAI 2023 Poster 7 Acute Allergic Rhinitis Increases Endogenous Epinephrine Resulting in Increased Heart Rate 678.5 KB ACAAI 2023 Poster 12 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of 2.0 mg neffy to Pediatric Subjects with a History of Allergic Reactions 806.5 KB ACAAI 2023 Poster 18 Pharmacokinetics/Pharmacodynamics of Intranasal Epinephrine in Subjects with and without Upper Respiratory Infections 522.5 KB AAAAI 2023 Poster 28 Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB AAAAI 2023 Poster 9 Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB AAAAI 2023 Poster 8 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB AAAAI 2023 Poster 14 ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last »
Investor Presentations ARS Pharma Corporate Presentation ARS Pharma Corporate Presentation 6.1 MB Aug 9, 2024 neffy® FDA Approval Call On August 9, 2024, we announced the FDA approval of neffy for adults and children 30 kg or greater in body weight. Supporting Materials neffy FDA Approval Call (August 2024) 5.9 MB Mar 7, 2024 at 1:00 PM EST Neffy® Investor Day On March 7, 2024, we hosted a virtual neffy Investor Day event showcasing the neffy product profile and anticipated commercialization strategy, including presentations from ARS Pharma senior management, as well as guest speakers. To view the webcast, click here Supporting Materials neffy investor day presentation (Mar 2024) 10.1 MB Scientific Publications JACI: In Practice Self-Administration Dosing Publication Adult pharmacokinetics of self-administration of epinephrine nasal spray 2.0 mg… JACI 2023 Single and Repeat Dose Publication Pharmacokinetics/pharmacodynamics of epinephrine after single and repeat admini… Scientific Presentations AAAAI 2024 Epinephrine Utilization A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB AAAAI 2024 Poster CMC Comparative Stability of Three Epinephrine Products Under Extreme Temperature Conditions 514.3 KB AAAAI 2024 Poster EPI 10 Pediatric Doses of neffy (epinephrine nasal spray) Demonstrate Pharmacokinetic Profiles Equivalent to Epinephrine Injection Products 649 KB ACAAI 2023 Poster 7 Acute Allergic Rhinitis Increases Endogenous Epinephrine Resulting in Increased Heart Rate 678.5 KB ACAAI 2023 Poster 12 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of 2.0 mg neffy to Pediatric Subjects with a History of Allergic Reactions 806.5 KB ACAAI 2023 Poster 18 Pharmacokinetics/Pharmacodynamics of Intranasal Epinephrine in Subjects with and without Upper Respiratory Infections 522.5 KB AAAAI 2023 Poster 28 Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB AAAAI 2023 Poster 9 Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB AAAAI 2023 Poster 8 A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB AAAAI 2023 Poster 14 ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last »
A Survey of Allergists, Pediatricians, and Primary Care Physicians About the Utilization of Epinephrine 1.1 MB
Pediatric Doses of neffy (epinephrine nasal spray) Demonstrate Pharmacokinetic Profiles Equivalent to Epinephrine Injection Products 649 KB
A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of 2.0 mg neffy to Pediatric Subjects with a History of Allergic Reactions 806.5 KB
Pharmacokinetics/Pharmacodynamics of Intranasal Epinephrine in Subjects with and without Upper Respiratory Infections 522.5 KB
Epinephrine Auto-Injector (EAI) Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey 2.2 MB
Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) 2.5 MB
A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions 1.1 MB
ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis 1.1 MB
